statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	575
IT - Italia	285
RU - Federazione Russa	227
SG - Singapore	164
CN - Cina	139
BR - Brasile	106
GB - Regno Unito	58
VN - Vietnam	58
HK - Hong Kong	44
KR - Corea	42
IE - Irlanda	37
FR - Francia	35
DE - Germania	26
NL - Olanda	25
IN - India	23
ZA - Sudafrica	21
SE - Svezia	19
MX - Messico	15
FI - Finlandia	14
CA - Canada	11
UA - Ucraina	9
BD - Bangladesh	8
EC - Ecuador	8
JP - Giappone	7
PL - Polonia	7
AR - Argentina	6
AT - Austria	6
TR - Turchia	5
ES - Italia	4
ID - Indonesia	4
CI - Costa d'Avorio	3
DZ - Algeria	3
HU - Ungheria	3
IQ - Iraq	3
JO - Giordania	3
KE - Kenya	3
MA - Marocco	3
PE - Perù	3
PY - Paraguay	3
SV - El Salvador	3
UZ - Uzbekistan	3
AE - Emirati Arabi Uniti	2
CO - Colombia	2
EG - Egitto	2
IR - Iran	2
KG - Kirghizistan	2
MY - Malesia	2
NG - Nigeria	2
NP - Nepal	2
VE - Venezuela	2
AU - Australia	1
AZ - Azerbaigian	1
BE - Belgio	1
BN - Brunei Darussalam	1
BO - Bolivia	1
CH - Svizzera	1
CL - Cile	1
CR - Costa Rica	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DO - Repubblica Dominicana	1
EE - Estonia	1
GT - Guatemala	1
HN - Honduras	1
IL - Israele	1
KH - Cambogia	1
KZ - Kazakistan	1
LB - Libano	1
LT - Lituania	1
LV - Lettonia	1
OM - Oman	1
PH - Filippine	1
PK - Pakistan	1
PT - Portogallo	1
RO - Romania	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TN - Tunisia	1
UY - Uruguay	1
Totale	2.069

Nome	#
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients	369
A NOVEL APPROACH TO UNRAVEL THE RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F-PROTEIN FUNCTIONAL ANTIBODY REPERTOIRE IN ADULT HEALTHY DONORS	207
Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses	190
Emerging roles of SARS-CoV-2 Spike-ACE2 in immune evasion and pathogenesis	183
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations	170
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody	162
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees	150
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants	144
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma	142
Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection	141
SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines	137
The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees	126
Totale	2.121

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	4	0	0	0	0	0	0	0	0	0	0	0	4
2021/2022	94	11	7	5	4	7	9	5	9	3	8	10	16
2022/2023	77	4	9	9	11	7	11	2	5	1	5	6	7
2023/2024	116	5	2	7	13	5	18	31	12	2	4	9	8
2024/2025	548	11	16	29	31	68	41	43	86	40	25	41	117
2025/2026	1.230	108	173	162	186	234	43	100	27	49	89	46	13
Totale													2.121